Last $163.92 USD
Change Today -1.30 / -0.79%
Volume 910.5K
ILMN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILMN) Snapshot

Open
$164.97
Previous Close
$165.22
Day High
$165.52
Day Low
$162.78
52 Week High
07/24/14 - $185.00
52 Week Low
10/9/13 - $72.77
Market Cap
22.9B
Average Volume 10 Days
1.1M
EPS TTM
$1.67
Shares Outstanding
139.4M
EX-Date
--
P/E TM
98.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILMN)

illumina inc (ILMN) Details

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology are designed to meet the various demands of a range of sequencing applications; and array platforms consist of HiScan and iScan systems that are array scanners, which support the imaging of array-based genetic analysis products. It also offers various sample preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping and whole genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has strategic partnerships with AstraZeneca PLC; Janssen Biotech, Inc.; and Sanofi to focus on the transition from single-analyte companion diagnostics to panel-based assays that select for companion therapeutics. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,000 Employees
Last Reported Date: 02/18/14
Founded in 1998

illumina inc (ILMN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President and Director
Total Annual Compensation: $153.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $447.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.1K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $449.6K
Compensation as of Fiscal Year 2013.

illumina inc (ILMN) Key Developments

GenoLogics Enters Agreement with Illumina to Provide Laboratory Information System for HiSeq X Ten System

GenoLogics announced it has been selected by Illumina as the preferred laboratory information management system (LIMS) provider to support HiSeq X Ten sequencing system customers. Under the agreement, the companies are working closely to provide support for HiSeq X Ten whole-genome workflows and analysis pipelines, including those to be used inside of Illumina. Additionally, Illumina will be using GenoLogics' LIMS to support its collaboration with Genomics England to sequence 100,000 genomes. The agreement pairs the $1,000 genome with the preeminent laboratory information management system, further empowering the sequencing community to sequence human whole genomes.

AstraZeneca and Illumina Inc. Partner to Develop NGS Panel for Companion Diagnostics

AstraZeneca has entered into a collaboration with Illumina Inc. to develop its next generation sequencing, or NGS, platform for companion diagnostic tests applicable across AstraZeneca's oncology portfolio. In the first instance, AstraZeneca intends to apply Illumina's technology to a novel companion diagnostic test in pivotal studies for one of its investigational oncology compounds. Illumina's NGS technology allows rapid sequencing of multiple genes in a much faster and cheaper way than traditional DNA sequencing methods. Under the collaboration, it will be used to screen a panel of several gene sequences, scanning for all possible genetic variants - known and unknown - rather than specified mutations from a single tumour sample. The comprehensive information obtained from sequencing full genes will be used to predict which patients will respond to certain treatments, and will go through appropriate regulation. Doctors are increasingly using companion diagnostic tests as an essential part of personalised healthcare to help them understand the causes of disease at a molecular level.

Illumina Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 02:55 PM

Illumina Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 02:55 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Jay T. Flatley, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $163.92 USD -1.30

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $165.82 USD -2.13
Avago Technologies Ltd $87.00 USD -0.11
Sigma-Aldrich Corp $136.01 USD -0.27
UCB SA €72.55 EUR +0.67
Vertex Pharmaceuticals Inc $112.31 USD -1.59
View Industry Companies
 

Industry Analysis

ILMN

Industry Average

Valuation ILMN Industry Range
Price/Earnings 100.0x
Price/Sales 13.4x
Price/Book 21.3x
Price/Cash Flow 89.9x
TEV/Sales 12.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.